ASCLF yields 110.50% · DVY yields 3.50%● Live data
📍 ASCLF pulled ahead of the other in Year 1
Combined, ASCLF + DVY cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ASCLF + DVY for your $10,000?
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Full ASCLF Calculator →The iShares Select Dividend ETF seeks to track the investment results of an index composed of relatively high dividend paying U.S. equities.
Full DVY Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.